FiercePharma

New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

VENTURE-AF, the First Global, Prospective, Randomized Trial of Any Novel Oral Anticoagulant in this Setting, Presented as Late-Breaking Clinical Trial Raritan, NJ (May 14, 2015) - Janssen ...
FiercePharma

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome RARITAN, N.J., June 28, 2013 -- Janssen Research & ...
Nasdaq

XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World ...

NEW ORLEANS, March 18, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new real-world study, which found newly diagnosed patients with ...
Business Insider

FDA Mini-Sentinel Assessment Confirms Safety and Effectiveness of XARELTO® (rivaroxaban) and its Association with a Lower Risk of Ischemic Stroke vs. Warfarin

TITUSVILLE, N.J., Jan. 16, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced findings from the U.S. Food and Drug Administration's (FDA) Mini-Sentinel ...
Nasdaq

XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist ...

People who take a blood thinner medicine (anticoagulant) like XARELTO®, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot ...
FierceBiotech

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome Raritan, NJ (May 23, ...
FOX31 Denver

Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization

New exploratory analysis demonstrates consistent results of XARELTO ® in treating elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention ...
Atlanta Journal-Constitution

Is the anticoagulant Xarelto affected by grapefruit?

Q: You often speak of food interactions with the blood thinner warfarin (Coumadin), but rarely address the anticoagulant Xarelto. I take Xarelto for atrial fibrillation and would like to know what ...
Business Insider

XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist ...

TITUSVILLE, N.J., March 11, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from a large, real-world meta-analysis of 95 studies ...
Houston Chronicle

Is the anticoagulant Xarelto affected by grapefruit?

Q: You often speak of food interactions with the blood thinner warfarin (Coumadin), but rarely address the anticoagulant Xarelto. I take Xarelto for atrial fibrillation and would like to know what ...